Morgens Waterfall Vintiadis & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,300	Closed	-$3.47M	–	29
2024 Q3	$3.47M	Hold	3,300	–	–	2.69%	19
2024 Q2	$3.47M	Sell	3,300 -600	-15%	-$582K	2.64%	22
2024 Q1	$3.75M	Sell	3,900 -200	-5%	-$190K	2.59%	20
2023 Q4	$3.6M	Buy	4,100 +2,600	+173%	+$2.14M	2.68%	20
2023 Q3	$1.23M	Hold	1,500	–	–	1%	25
2023 Q2	$1.08M	Hold	1,500	–	–	0.77%	28
2023 Q1	$1.23M	Hold	1,500	–	–	1.01%	29
2022 Q4	$1.08M	Buy	1,500 +400	+36%	+$295K	0.94%	34
2022 Q3	$758K	Buy	+1,100	New	+$692K	0.83%	31
2022 Q2	–	Sell	-3,900	Closed	-$2.72M	–	34
2022 Q1	$2.72M	Buy	+3,900	New	+$2.47M	1.71%	20
2021 Q4	–	Sell	-3,500	Closed	-$2.12M	–	34
2021 Q3	$2.12M	Hold	3,500	–	–	1.09%	25
2021 Q2	$1.96M	Buy	+3,500	New	+$1.77M	1%	28

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's REGN Position: Q4 2024 in Review

Morgens Waterfall Vintiadis & Co sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 3,300 shares — an estimated $3.47M sold.

Morgens Waterfall Vintiadis & Co first reported a position in REGN in Q2 2021 and held it in 12 quarters. The position peaked at $3.75M in Q1 2024. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Morgens Waterfall Vintiadis & Co reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 3,300 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $3.47M.
Morgens Waterfall Vintiadis & Co first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 12 quarters.
Morgens Waterfall Vintiadis & Co's Regeneron Pharmaceuticals position peaked at $3.75M in Q1 2024.
1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q4 2024, filed 14 Feb 2025.